Fundraising Fox

Merge Bio Therapeutics

Cambridge, US · Founded 2025 · Delaware corporation · 1 known investors

Founders & leadership

CH
Clinton HansenExecutive
WW
Wesley WongNamed on SEC filing

Board

SLSteve Liapis
Steve LiapisinBoard directorManaging Director at Northpond Ventures
EQElias Quijano
Elias QuijanoinBoard directorPrincipal at Northpond Ventures

Investors · 1

Northpond VenturesreportedBethesda · $100K – $5Mvia Steve Liapis · board

Reported raises · per SEC filings

Form D private placements

$5M disclosed across 1 round · 2025

▶$5MraisedSep 2025 · 1 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • Mark LipsteinPromoter
  • Steve LiapisDirector
  • Clinton HansenExecutive Officer, Promoter
  • Elias QuijanoDirector
  • Wesley WongExecutive Officer, Director, Promoter
  • Darren YangPromoter
Offering amount
$15M
Amount sold
$5M
First sale
Aug 2025
Incorporated
Corporation, Delaware, 2025
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

Who are Merge Bio Therapeutics's investors?
Merge Bio Therapeutics's investors include Northpond Ventures.
How much funding has Merge Bio Therapeutics raised?
Merge Bio Therapeutics has disclosed $5M raised across 1 round.
Where is Merge Bio Therapeutics headquartered?
Merge Bio Therapeutics is headquartered in Cambridge, US.